Limits...
Treatment of HIV-associated facial lipoatrophy: impact on infection progression assessed by viral load and CD4 count.

Soares FM, Costa IM - An Bras Dermatol (2013 Jul-Aug)

Bottom Line: Male and female patients, aged over 18 years, with clinically detectable FL and who had never been treated were included in the study.PMMA implantation was done to fill atrophic areas.After treatment, the average increased to 548.61.

View Article: PubMed Central - PubMed

Affiliation: University of Brasilia, Department of Health of the Federal District, BrasíliaDF, Brazil.

ABSTRACT

Background: HIV/AIDS-Associated Lipodystrophy Syndrome includes changes in body fat distribution, with or without metabolic changes. The loss of fat from the face, called facial lipoatrophy, is one of the most stigmatizing signs of the syndrome.

Objectives: To evaluate the effect of FL treatment using polymethylmethacrylate (PMMA) implants on disease progression, assessed by viral load and CD4 cell count.

Methods: This was a prospective study of 44 patients treated from July 2009 to December 2010. Male and female patients, aged over 18 years, with clinically detectable FL and who had never been treated were included in the study. PMMA implantation was done to fill atrophic areas. Laboratory tests were conducted to measure viral load and CD4 count before and after treatment.

Results: Of the 44 patients, 72.72% were male and 27.27% female, mean age of 44.38 years. Before treatment, 82% of patients had undetectable viral load, which increased to 88.6% after treatment, but without statistical significance (p = 0.67). CD4 count before treatment ranged from 209 to 1293, averaging 493.97. After treatment, the average increased to 548.61. The increase in CD4 count after treatment was statistically significant with p = 0.02.

Conclusion: The treatment of FL with PMMA implants showed a statistically significant increase in CD4 count after treatment, revealing the impact of FL treatment on disease progression. Viral load before and after treatment did not vary significantly.

Show MeSH

Related in: MedlinePlus

The same patient after PMMA implantation. Six months after the end of treatment,the patient presented a CD4 count of 1485 cells /mm3, the highestincrease observed in this study
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3760932&req=5

f02: The same patient after PMMA implantation. Six months after the end of treatment,the patient presented a CD4 count of 1485 cells /mm3, the highestincrease observed in this study

Mentions: The highest increase found in CD4 count was that of a patient who had 581 cells/mm3before treatment and 1485cells/mm 3after treatment (Figures 1 and 2).


Treatment of HIV-associated facial lipoatrophy: impact on infection progression assessed by viral load and CD4 count.

Soares FM, Costa IM - An Bras Dermatol (2013 Jul-Aug)

The same patient after PMMA implantation. Six months after the end of treatment,the patient presented a CD4 count of 1485 cells /mm3, the highestincrease observed in this study
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3760932&req=5

f02: The same patient after PMMA implantation. Six months after the end of treatment,the patient presented a CD4 count of 1485 cells /mm3, the highestincrease observed in this study
Mentions: The highest increase found in CD4 count was that of a patient who had 581 cells/mm3before treatment and 1485cells/mm 3after treatment (Figures 1 and 2).

Bottom Line: Male and female patients, aged over 18 years, with clinically detectable FL and who had never been treated were included in the study.PMMA implantation was done to fill atrophic areas.After treatment, the average increased to 548.61.

View Article: PubMed Central - PubMed

Affiliation: University of Brasilia, Department of Health of the Federal District, BrasíliaDF, Brazil.

ABSTRACT

Background: HIV/AIDS-Associated Lipodystrophy Syndrome includes changes in body fat distribution, with or without metabolic changes. The loss of fat from the face, called facial lipoatrophy, is one of the most stigmatizing signs of the syndrome.

Objectives: To evaluate the effect of FL treatment using polymethylmethacrylate (PMMA) implants on disease progression, assessed by viral load and CD4 cell count.

Methods: This was a prospective study of 44 patients treated from July 2009 to December 2010. Male and female patients, aged over 18 years, with clinically detectable FL and who had never been treated were included in the study. PMMA implantation was done to fill atrophic areas. Laboratory tests were conducted to measure viral load and CD4 count before and after treatment.

Results: Of the 44 patients, 72.72% were male and 27.27% female, mean age of 44.38 years. Before treatment, 82% of patients had undetectable viral load, which increased to 88.6% after treatment, but without statistical significance (p = 0.67). CD4 count before treatment ranged from 209 to 1293, averaging 493.97. After treatment, the average increased to 548.61. The increase in CD4 count after treatment was statistically significant with p = 0.02.

Conclusion: The treatment of FL with PMMA implants showed a statistically significant increase in CD4 count after treatment, revealing the impact of FL treatment on disease progression. Viral load before and after treatment did not vary significantly.

Show MeSH
Related in: MedlinePlus